Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.
Cellerant's Press Releases
December 5, 2014
Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients with Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting
September 11, 2014
Cellerant Therapeutics awarded $47.5 million under existing U.S. Government contract to support development of CLT-008.
May 12, 2014
Cellerant Therapeutics Announces Timothy Fong as Vice President of Cellular Technologies and Jagath Reddy Junutula as Vice President of Antibody Discovery & Development